The expansion focuses on precision antibody engineering
Traditional monoclonal antibodies (mAbs) often face significant clinical hurdles, including “on-target, off-tumour” toxicity and rapid antigen-mediated clearance. To address these challenges, Creative Biolabs has synthesised a multidimensional approach to biologic design, prioritising conditional activation and enhanced pharmacokinetics.
“Our goal is to transform antibodies from simple binding agents into intelligent, environment-responsive systems,” said a senior scientist at Creative Biolabs. “By leveraging chemical and biological triggers—such as pH gradients in endosomes or specific protease activity in the tumour microenvironment—we can significantly reduce systemic toxicity while maximising local efficacy.”
A holistic suite of engineered solutions
The newly expanded platform features several core technologies designed for diverse therapeutic requirements:
-
Active antigen clearance: Unlike traditional neutralisers, eliminating antibodies are engineered to actively sweep soluble antigens from circulation. By enhancing FcRn binding at neutral pH, these antibodies can achieve a 30-fold reduction in required dosage, making them ideal for high-concentration targets like C5 or circulating toxins.
-
Precision masking technology: To protect healthy tissues, the company’s antitumour antibody prodrugs utilise affinity masking. These molecules remain inactive in systemic circulation and are only triggered by specific enzymes within the tumour.
-
Environmental sensitivity: pH-dependent antibodies are designed to bind antigens at physiological pH (7.4) and release them in the acidic endosome (pH 6.0). This recycling mechanism allows a single antibody molecule to neutralise multiple antigens, extending in vivo half-life.
-
Analytical support: To facilitate these complex designs, the platform provides specialized proteolytic enzymes for precise antibody fragmentation and deglycosylation, ensuring rigorous quality control and characterisation.
Technical insights: Addressing industry challenges
To assist researchers in navigating these advanced modalities, Creative Biolabs has integrated comprehensive technical assessments into their workflow. Common inquiries addressed by the platform include:
-
Efficiency Gains: The pH-dependent platform offers an average 40% increase in lead screening efficiency by utilising sequence-based histidine mutation prediction.
-
Dosage Reduction: Industry studies indicate that eliminating antibodies can reduce plasma antigen concentrations by 50-fold to 1000-fold compared to conventional therapies.
-
Safety Protocols: Rigorous Fc engineering is employed to minimise immunogenicity while maximising the specific therapeutic index of prodrug candidates.
